


## NOVEL ROUTE TO QUINOLINES VIA RECYCLIZATION OF FURANS

A. V. Butin<sup>1\*</sup>, F. A. Tsiunchik<sup>1</sup>, O. N. Kostyukova<sup>1</sup>, and I. V. Trushkov<sup>2</sup>

**Keywords:** furans, quinolines, Bischler-Napieralski reaction.

The Bischler-Napieralski reaction is a powerful tool for the construction of nitrogen-containing heterocyclic compounds through the formation of a new C–C bond as the result of the reaction of an electrophilic carbon atom with an aromatic or heterocyclic nucleus. It is generally used in the synthesis of 3,4-dihydroisoquinolines from phenylethylamine amides or  $\beta$ -carboline from tryptamine amides [1, 2] but it can also be used for the annelation of a pyridine ring to other heterocyclic compounds [3-6]. In addition, variation of the linkage joining the aromatic fragment and the amide function permits the synthesis of a wide range of nitrogen-containing heterocycles. Thus, under the indicated conditions, 2-acylamino diphenylmethanes give dibenzoazepines [7] and their thienyl analogs yield thienoazepines [8].



\* To whom correspondence should be addressed, e-mail: alexander\_butin@mail.ru.

<sup>1</sup>Research Institute of Heterocyclic Compounds Chemistry, Kuban State Technological University, Krasnodar 350072, Russia.

<sup>2</sup>M. V. Lomonosov State University, Chemistry Faculty, Moscow 119992, Russia.

Translated from *Khimiya Geterotsiklicheskikh Soedinenii*, No. 12, pp. 1900-1903, December, 2010.  
Original article submitted October 7, 2010.

A similar reaction has not been reported for 2-(2-acylamino-benzyl)furans although it is known that 2-[2-(aminocarbamoyl)phenylthio]furans give furo[2,3-*b*][1,5]benzothiazepines when treated with phosphorus oxychloride in the presence of P<sub>2</sub>O<sub>5</sub> [9]. In that connection, the aim of this work was to study the possibility of preparing the furo[3,2-*c*]benzazepine **1** under Bischler-Napieralski conditions from the 2-(2-acylamino-benzyl)furan **2**.

When compound **2** (prepared by acylation of the available benzylfuran **3** with benzoyl chloride [10]) was refluxed in benzene in the presence of excess phosphorus oxychloride the quinoline **4** was obtained instead of the expected furoazepine **1**. Evidently, its formation results from electrophilic attack of the formed iminium ion not at the β-position of the furan ring but at the α-carbon atom of the furan. There then occurs an electrophilic opening of the furan ring to form the aromatic quinoline system.

IR spectra were taken on a Shimadzu IR Prestige-21 instrument for KBr tablets. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker DPX-300 spectrometer (300 and 75 MHz respectively) using DMSO-*d*<sub>6</sub> (for compound **2**) or CDCl<sub>3</sub> (compound **4**). The standards used were the residual protons of the deuterated solvent CDCl<sub>3</sub> (7.25 ppm for <sup>1</sup>H and 77.0 ppm for <sup>13</sup>C) or DMSO-*d*<sub>6</sub> (2.50 ppm for <sup>1</sup>H and 39.5 ppm for <sup>13</sup>C). Mass spectra were obtained on a Kratos MS-30 spectrometer by EI with ionizing energy 70 eV and ionization chamber temperature 200°C.

**N-{2-[(5-Methyl-2-furyl)methyl]-4,5-dimethoxyphenyl}benzamide (2)**. A solution of benzoyl chloride (2.1 g, 15 mmol) in benzene (25 ml) was added dropwise with stirring to a solution of compound **3** (2.47 g, 10 mmol) in benzene (30 ml), stirred at room temperature for 1 h (TLC monitoring), and then poured into water (100 ml). The mixture obtained was neutralized with NaHCO<sub>3</sub> and left for 2 h. The benzene layer was separated and the aqueous extracted with ethyl acetate (2×30 ml). The combined organic fractions were dried over Na<sub>2</sub>SO<sub>4</sub> and filtered. The solvent was removed *in vacuo* and the residue was dissolved in a mixture of methylene chloride and petroleum ether (1:8). The obtained solution was passed through a layer of silica gel and the solvent was evaporated. Recrystallization from a mixture of methylene chloride and petroleum ether (1:5) gave compound **2** (2.53 g, 72%) as a white powder with mp 110°C. IR spectrum, ν, cm<sup>-1</sup>: 3260, 1644, 1612, 1516, 1468, 1308, 1284, 1260, 1220, 1092, 712. <sup>1</sup>H NMR spectrum, δ, ppm (*J*, Hz): 2.25 (3H, s, CH<sub>3</sub>); 3.87 (6H, s, OCH<sub>3</sub>); 3.90 (2H, s, CH<sub>2</sub>); 5.89 (1H, d, *J* = 3.3, H furan); 5.94 (1H, d, *J* = 3.3, H furan); 6.75 (1H, s, Ph); 7.44-7.58 (3H, m, Ph); 7.61 (1H, s, Ph); 7.85-7.87 (2H, m, Ph); 8.38 (1H, s, NH). <sup>13</sup>C NMR spectrum, δ, ppm: 13.5, 31.2, 55.9, 56.0, 106.4, 106.9, 108.1, 112.9, 122.0, 127.0 (2C), 128.6 (2C), 128.9, 131.7, 134.7, 146.3, 147.8, 151.3, 151.5, 165.5. Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 351 [M]<sup>+</sup> (78), 247 (24), 246 (76), 106 (12), 105 (95), 95 (13), 77 (100), 59 (48), 43 (55). Found, %: C 71.61; H 6.11; N 3.81. C<sub>21</sub>H<sub>21</sub>NO<sub>4</sub>. Calculated, %: C 71.78; H 6.02; N 3.99.

**(3E)-4-(6,7-Dimethoxy-2-phenylquinolin-3-yl)but-3-en-2-one (4)**. POCl<sub>3</sub> (25 ml) was added to a solution of compound **2** (0.53 g, 1.5 mmol) in benzene (10 ml) and refluxed for 1.5 h (TLC monitoring). The reaction mixture was then poured onto crushed ice (500 g), neutralized with aqueous NaOH solution (3.5 M, 350 ml), and extracted with methylene chloride (3×150 ml). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was removed *in vacuo*. The reaction product was separated by column chromatography on 50-160 μm silica gel using methylene chloride and petroleum ether (1:3) as eluent. Recrystallization from a mixture of methylene chloride and petroleum ether (1:4) gave quinoline **4** (0.31 g, 61%) as a light-yellow powder with mp 200-201°C. IR spectrum, ν, cm<sup>-1</sup>: 1664, 1616, 1588, 1496, 1432, 1392, 1260, 1228, 1212, 1132, 1008, 704. <sup>1</sup>H NMR spectrum, δ, ppm (*J*, Hz): 2.28 (3H, s, CH<sub>3</sub>); 4.03 (3H, s, OCH<sub>3</sub>); 4.04 (3H, s, OCH<sub>3</sub>); 6.73 (1H, d, *J* = 16.2 =CH); 7.10 (1H, s, H Ar); 7.46-7.54 (4H, m, H Ar); 7.58-7.62 (2H, m, H Ar); 7.66 (1H, d, *J* = 16.2, =CH); 8.30. (1H, s, H Py). <sup>13</sup>C NMR spectrum, δ, ppm: 26.9, 56.0, 56.2, 104.8, 107.9, 122.5, 124.8, 128.3 (3C), 128.6, 129.7 (2C), 132.8, 139.3, 142.0, 145.6, 150.2, 153.7, 157.1, 198.2. Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 333 [M]<sup>+</sup> (27), 290 (100), 275 (31), 274 (38), 246 (30), 217 (26), 101 (29), 59 (55), 43 (57). Found, %: C 75.37; H 5.60; N 4.19. C<sub>21</sub>H<sub>19</sub>NO<sub>3</sub>. Calculated, %: C 75.66; H 5.74; N 4.20

This work was carried out within the Federal Target Program "Russian Science and Science Teaching Innovation" for the years 2009-2013 (application 1.3.1, State Contract P2347).

## REFERENCES

1. B. E. Love, *Org. Prep. Proced. Int.*, **28**, 1 (1996).
2. M. Chrzanowska and M. D. Rozwadowska, *Chem. Rev.*, **104**, 3341 (2004).
3. M. Ohkubo, A. Kuno, K. Katsuta, Y. Ueda, K. Shirakawa, H. Nakanishi, T. Kinoshita, and H. Takasugi, *Chem. Pharm. Bull.*, **44**, 778 (1996).
4. W. Zheng, V. I. Nikulin, A. A. Konkar, S. S. Vansal, G. Shams, D. R. Feller, and D. D. Miller, *J. Med. Chem.*, **42**, 2287 (1999).
5. J. Liu, Z. Diwu, W.-Y. Leung, Y. Lu, B. Patch, and R. P. Haugland, *Tetrahedron Lett.*, **44**, 4355 (2003).
6. J. Guillon, I. Forfar, M. Mamani-Matsuda, V. Desplat, M. Saliege, D. Thiolat, S. Massip, A. Tabourier, J.-M. Leger, B. Dufaure, G. Haumont, C. Jarry, and D. Mossalayi, *Bioorg. Med. Chem.*, **15**, 194 (2007).
7. J. I. Andres, J. Alcazar, J. M. Alonso, A. Diaz, J. Fernandez, P. Gil, L. Iturrino, E. Matesanz, T. F. Meert, A. Megens, and V. K. Sipido, *Bioorg. Med. Chem. Lett.*, **12**, 243 (2002).
8. F. Hunziker, R. Fischer, P. Kipfer, J. Schmutz, H. R. Bürki, E. Eichenberger, and T. G. White, *Eur. J. Med. Chem.*, **16**, 391 (1981).
9. M. Ogawa, J. Koyanagi, K. Sakuma, A. Tanaka, and K. Yamamoto, *J. Heterocycl. Chem.*, **36**, 819 (1999).
10. A. V. Butin, S. K. Smirnov, T. A. Stroganova, W. Bender, and G. D. Krapivin, *Tetrahedron*, **63**, 474 (2007).